ALLO
Allogene Therapeutics Inc (ALLO)
Healthcare • NASDAQ • $2.07-0.24%
- Symbol
- ALLO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $2.07
- Daily Change
- -0.24%
- Market Cap
- $690.31M
- Trailing P/E
- N/A
- Forward P/E
- -2.92
- 52W High
- $4.46
- 52W Low
- $0.98
- Analyst Target
- $8.49
- Dividend Yield
- N/A
- Beta
- 0.46
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candi…
Company websiteResearch ALLO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.